{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:08:08Z","timestamp":1775264888233,"version":"3.50.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":286,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82102978"],"award-info":[{"award-number":["82102978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Currently, the prognosis for metastatic colorectal cancer (mCRC) still remains poor. The management of mCRC has become manifold because of the varied advances in the systemic and topical treatment approaches. For patients with limited number of metastases, radical local therapy plus systemic therapy can be a good choice to achieve long-term tumor control. In this study, we aimed to explore the efficacy and safety of the combination of fruquintinib, tislelizumab, and stereotactic ablative radiotherapy (SABR) in mCRC (RIFLE study).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RIFLE was designed as a single-center, single-arm, prospective Phase II clinical trial. A total of 68 mCRC patients who have failed the first-line standard treatment will be recruited in the safety run-in phase (n\u2009=\u20096) and the expansion phase (n\u2009=\u200962), respectively. Eligible patients will receive SABR followed by fruquintinib (5\u2009mg, d1\u201314, once every day) and tislelizumab (200\u2009mg, d1, once every 3\u2009weeks) within 2\u00a0weeks from completion of radiation. The expansion phase starts when the safety of the treatment is determined (dose limiting toxicity occur in no more than one-sixth of patients in the run-in phase). The primary end point is the objective response rate. The secondary end points include the disease control rate, duration of response, 3-year progression-free survival rate, 3-year overall survival rate, and toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this trial will provide a novel insight into SABR in combination with PD-1 antibody and vascular endothelial growth factor receptor inhibitor in the systematic treatment of metastatic colorectal cancer, which is expected to provide new therapeutic strategies and improve the prognosis for mCRC patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>NCT04948034 (ClinicalTrials.gov).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/gastro\/goad063","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:50:32Z","timestamp":1697104232000},"source":"Crossref","is-referenced-by-count":10,"title":["RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-8042","authenticated-orcid":false,"given":"Kun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juefeng","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiazhou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7825-2679","authenticated-orcid":false,"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai, P. R. China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, P. R. China"},{"name":"Shanghai Key Laboratory of Radiation Oncology , Shanghai, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"2023101209501972100_goad063-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J National Cancer Center"},{"key":"2023101209501972100_goad063-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2023101209501972100_goad063-B3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023101209501972100_goad063-B4","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"2023101209501972100_goad063-B5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"2023101209501972100_goad063-B6","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B7","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023101209501972100_goad063-B8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"2023101209501972100_goad063-B9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2023101209501972100_goad063-B10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the Game in Immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"key":"2023101209501972100_goad063-B11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3322\/caac.21358","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2023101209501972100_goad063-B12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"2023101209501972100_goad063-B13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2023101209501972100_goad063-B14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023101209501972100_goad063-B15","doi-asserted-by":"crossref","first-page":"e426-34","DOI":"10.1016\/S1470-2045(14)70026-9","article-title":"Combination of stereotactic ablative body radiation with targeted therapies","volume":"15","author":"Zeng","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023101209501972100_goad063-B16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5301\/tj.5000701","article-title":"Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer","volume":"104","author":"Mazzola","year":"2018","journal-title":"Tumori"},{"issue":"3","key":"2023101209501972100_goad063-B17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001657","article-title":"Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages","volume":"9","author":"Ou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023101209501972100_goad063-B18","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B19","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group","volume":"37","author":"Benedict","year":"2013","journal-title":"Med Phys"},{"key":"2023101209501972100_goad063-B20","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2016.05.004","article-title":"Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases","volume":"6","author":"Al-Hallaq","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"2023101209501972100_goad063-B21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1245\/s10434-010-1405-5","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases","volume":"18","author":"Rule","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2023101209501972100_goad063-B23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","article-title":"Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023101209501972100_goad063-B24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","article-title":"Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases","volume":"99","author":"Mcpartlin","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023101209501972100_goad063-B25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00066-012-0290-1","article-title":"Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events","volume":"189","author":"Inoue","year":"2013","journal-title":"Strahlenther Onkol"},{"key":"2023101209501972100_goad063-B26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.radonc.2013.05.024","article-title":"Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?","volume":"107","author":"Widder","year":"2013","journal-title":"Radiother Oncol"},{"key":"2023101209501972100_goad063-B27","doi-asserted-by":"crossref","first-page":"369820","DOI":"10.1155\/2012\/369820","article-title":"Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence","volume":"2012","author":"Inoue","year":"2012","journal-title":"Pulm Med"},{"key":"2023101209501972100_goad063-B28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023101209501972100_goad063-B30","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"ANDR\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2023101209501972100_goad063-B31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B32","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2023101209501972100_goad063-B33","article-title":"Identification of immune cell infiltration landscape for predicting prognosis of colorectal cancer","volume":"11","author":"Wu","year":"2023","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2023101209501972100_goad063-B34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clcc.2019.08.001","article-title":"Efficacy of PD-1 blockade in refractory microsatellite-stable colorectal cancer with high tumor mutation burden","volume":"18","author":"Gong","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"2023101209501972100_goad063-B35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2023101209501972100_goad063-B36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2023101209501972100_goad063-B37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"2023101209501972100_goad063-B38","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"2023101209501972100_goad063-B39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma","volume":"39","author":"Mcbride","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023101209501972100_goad063-B41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2023101209501972100_goad063-B42","first-page":"1611","volume-title":"JCO","author":"Luke","year":"2018"},{"key":"2023101209501972100_goad063-B43","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"key":"2023101209501972100_goad063-B44","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"2023101209501972100_goad063-B45","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2021.39.15_suppl.3560","article-title":"Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer (CRC)","volume":"39","author":"Fakih","year":"2021","journal-title":"JCO"},{"key":"2023101209501972100_goad063-B46","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1200\/JCO.2021.39.15_suppl.3564","article-title":"LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014results from the colorectal cancer cohort","volume":"39","author":"Gomez-Roca","year":"2021","journal-title":"JCO"},{"key":"2023101209501972100_goad063-B47","doi-asserted-by":"crossref","first-page":"841977","DOI":"10.3389\/fonc.2022.841977","article-title":"Fruquintinib enhances the antitumor immune responses of anti-programmed death receptor-1 in colorectal cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"2023101209501972100_goad063-B48","doi-asserted-by":"crossref","first-page":"754881","DOI":"10.3389\/fonc.2021.754881","article-title":"Efficacy and safety of fruquintinib plus PD-1 inhibitors versus regorafenib plus PD-1 inhibitors in refractory microsatellite stable metastatic colorectal cancer","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"2023101209501972100_goad063-B49","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2021.39.15_suppl.2514","article-title":"Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer","volume":"39","author":"Guo","year":"2021","journal-title":"JCO"},{"key":"2023101209501972100_goad063-B50","doi-asserted-by":"crossref","first-page":"e15551","DOI":"10.1200\/JCO.2021.39.15_suppl.e15551","article-title":"A phase ib trial of assessing the safety and preliminary efficacy of a combination therapy of geptanolimab (GB 226) plus fruquintinib in patients with metastatic colorectal cancer (mCRC)","volume":"39","author":"Bai","year":"2021","journal-title":"JCO"},{"key":"2023101209501972100_goad063-B51","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3389\/fimmu.2018.03107","article-title":"Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer?","volume":"9","author":"Goedegebuure","year":"2018","journal-title":"Front Immunol"},{"key":"2023101209501972100_goad063-B52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2022.40.4_suppl.015","article-title":"Phase I\/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC)","volume":"40","author":"Barzi","year":"2022","journal-title":"JCO"},{"key":"2023101209501972100_goad063-B53","doi-asserted-by":"crossref","first-page":"686621","DOI":"10.3389\/fonc.2021.686621","article-title":"Safety of PD-1\/PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced hepatocellular carcinoma","volume":"11","author":"Zhong","year":"2021","journal-title":"Front Oncol"},{"key":"2023101209501972100_goad063-B54","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023101209501972100_goad063-B55","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023101209501972100_goad063-B56","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2023101209501972100_goad063-B57","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goad063\/52030240\/goad063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goad063\/52030240\/goad063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:50:55Z","timestamp":1697104255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goad063\/7308557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goad063","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,12,30]]},"article-number":"goad063"}}